Vernalis agrees $64.5 million deal for Cita
Vernalis will pay an initial consideration of $29.5 million, payable in Vernalis shares and assume certain of Cita’s liabilities. Vernalis may also pay up to a further $35
The US Food and Drug Administration (FDA) has approved PharmaEssentia’s Besremi (ropeginterferon alfa-2b-njft) to treat adults with essential thrombocythaemia (ET).